title: Development of an ex vivo human skin model for intradermal vaccination: tissue viability and Langerhans cell behaviour.
abstract: The presence of resident Langerhans cells (LCs) in the epidermis makes the skin an attractive target for DNA vaccination. However, reliable animal models for cutaneous vaccination studies are limited. We demonstrate an ex vivo human skin model for cutaneous DNA vaccination which can potentially bridge the gap between pre-clinical in vivo animal models and clinical studies. Cutaneous transgene expression was utilised to demonstrate epidermal tissue viability in culture. LC response to the culture environment was monitored by immunohistochemistry. Full-thickness and split-thickness skin remained genetically viable in culture for at least 72 h in both phosphate-buffered saline (PBS) and full organ culture medium (OCM). The epidermis of explants cultured in OCM remained morphologically intact throughout the culture duration. LCs in full-thickness skin exhibited a delayed response (reduction in cell number and increase in cell size) to the culture conditions compared with split-thickness skin, whose response was immediate. In conclusion, excised human skin can be cultured for a minimum of 72 h for analysis of gene expression and immune cell activation. However, the use of split-thickness skin for vaccine formulation studies may not be appropriate because of the nature of the activation. Full-thickness skin explants are a more suitable model to assess cutaneous vaccination ex vivo.
authors.affiliation: Gene Delivery Research Group, Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3NB, UK.
authors.forename: Keng Wooi
authors.initials: KW
authors.lastname: Ng
authors.forename: Marc
authors.initials: M
authors.lastname: Pearton
authors.forename: Sion
authors.initials: S
authors.lastname: Coulman
authors.forename: Alexander
authors.initials: A
authors.lastname: Anstey
authors.forename: Christopher
authors.initials: C
authors.lastname: Gateley
authors.forename: Anthony
authors.initials: A
authors.lastname: Morrissey
authors.forename: Christopher
authors.initials: C
authors.lastname: Allender
authors.forename: James
authors.initials: J
authors.lastname: Birchall
mesh_terms: D000328:Adult; D000368:Aged; D000078404:Epidermal Cells; D005260:Female; D015870:Gene Expression; D018014:Gene Transfer Techniques; D006801:Humans; D007271:Injections, Intradermal; D007801:Langerhans Cells / Q000166:cytology* / Q000276:immunology; D008875:Middle Aged; D009924:Organ Culture Techniques; D010957:Plasmids; D012867:Skin / Q000166:cytology* / Q000276:immunology; D014022:Tissue Survival; D019076:Transgenes; D014611:Vaccination
references.citation: J Clin Invest. 1996 Jun 15;97(12):2911-6
references.pmid: 8675706
references.citation: Histol Histopathol. 1998 Jul;13(3):775-83
references.pmid: 9690135
references.citation: Clin Exp Dermatol. 2000 Jul;25(5):413-8
references.pmid: 11012599
references.citation: Cytokine. 2005 Oct 21;32(2):67-70
references.pmid: 16153855
references.citation: Nature. 1977 Jul 21;268(5617):245-6
references.pmid: 887158
references.citation: Leg Med (Tokyo). 2004 Mar;6(1):25-31
references.pmid: 15177070
references.citation: J Drug Target. 2005 Aug;13(7):415-21
references.pmid: 16308210
references.citation: Br J Plast Surg. 2000 Jun;53(4):331-6
references.pmid: 10876260
references.citation: Proc Natl Acad Sci U S A. 2006 May 16;103(20):7783-8
references.pmid: 16672373
references.citation: J Immunol. 2006 Jun 15;176(12):7232-42
references.pmid: 16751366
references.citation: J Immunol. 2005 Feb 15;174(4):2220-7
references.pmid: 15699155
references.citation: Pharm Res. 2008 Feb;25(2):407-16
references.pmid: 17671832
references.citation: J Anat. 1980 Dec;131(Pt 4):669-82
references.pmid: 7216904
references.citation: Int J Pharm. 2006 Apr 7;312(1-2):15-23
references.pmid: 16469457
references.citation: Open Rheumatol J. 2008;2:17-22
references.pmid: 19088866
references.citation: J Invest Dermatol. 2006 Jan;126(1):32-41
references.pmid: 16417215
references.citation: Immunol Cell Biol. 2008 Jul;86(5):428-38
references.pmid: 18431356
references.citation: Toxicol In Vitro. 2006 Apr;20(3):347-54
references.pmid: 16182510
references.citation: Immunol Rev. 2004 Jun;199:9-26
references.pmid: 15233723
references.citation: Int Immunol. 2000 Jun;12(6):737-45
references.pmid: 10837401
references.citation: Lab Invest. 1995 Oct;73(4):521-31
references.pmid: 7474924
references.citation: J Investig Dermatol Symp Proc. 1999 Sep;4(2):164-8
references.pmid: 10536993
references.citation: J Burn Care Rehabil. 1991 Jul-Aug;12(4):306-12
references.pmid: 1939301
references.citation: Toxicol In Vitro. 2002 Oct;16(5):581-8
references.pmid: 12206825
references.citation: Exp Dermatol. 2006 Jun;15(6):421-31
references.pmid: 16689858
references.citation: J Cell Physiol. 1984 Oct;121(1):31-44
references.pmid: 6207187
references.citation: Exp Cell Res. 1954 Feb;6(1):246-8
references.pmid: 13142005
references.citation: Adv Drug Deliv Rev. 2006 Apr 20;58(1):68-89
references.pmid: 16564111
references.citation: J Invest Dermatol. 2001 Feb;116(2):313-8
references.pmid: 11180009
references.citation: Curr Drug Deliv. 2006 Jan;3(1):65-75
references.pmid: 16472095
references.citation: Methods Find Exp Clin Pharmacol. 1997 Jun;19(5):335-41
references.pmid: 9379782
references.citation: J Cutan Pathol. 1991 Feb;18(1):8-12
references.pmid: 2022768
references.citation: Cell Tissue Bank. 2008 Mar;9(1):19-29
references.pmid: 17458519
references.citation: J Invest Dermatol. 2006 Apr;126(4):787-96
references.pmid: 16439974
references.citation: J Immunol. 2009 Feb 1;182(3):1260-9
references.pmid: 19155471
references.citation: J Invest Dermatol. 2008 Jun;128(6):1470-5
references.pmid: 18185529
references.citation: Nature. 1977 Jul 21;268(5617):247-8
references.pmid: 329141
references.citation: Nature. 1977 Jul 21;268(5617):248-50
references.pmid: 329142
references.citation: J Trauma. 1988 Jul;28(7):1054-9
references.pmid: 2456402
references.citation: Skin Res Technol. 2003 Nov;9(4):321-30
references.pmid: 14641882
references.citation: Eur J Immunol. 2003 Oct;33(10):2645-54
references.pmid: 14515248
references.citation: J Dermatol Sci. 2007 Jan;45(1):23-30
references.pmid: 17123788
references.citation: In Vitro Cell Dev Biol. 1986 Jul;22(7):423-8
references.pmid: 2426243
references.citation: J Exp Med. 1990 Nov 1;172(5):1483-93
references.pmid: 2230654
references.citation: Drug Metab Dispos. 2007 Sep;35(9):1463-5
references.pmid: 17553916
references.citation: Proc Natl Acad Sci U S A. 1983 Mar;80(6):1650-4
references.pmid: 6572931
references.citation: J Immunol. 2001 Nov 15;167(10):5549-57
references.pmid: 11698425
references.citation: J Immunol. 2003 Jun 1;170(11):5483-90
references.pmid: 12759425
references.citation: J Immunol. 2006 Aug 15;177(4):2208-15
references.pmid: 16887980
references.citation: Prostate. 1997 Jun 15;32(1):43-8
references.pmid: 9207956
references.citation: Hum Gene Ther. 2009 Mar;20(3):181-9
references.pmid: 19301471
references.citation: Genet Vaccines Ther. 2003 Sep 16;1(1):2
references.pmid: 14606963
references.citation: Eur J Immunol. 2008 Nov;38(11):3050-9
references.pmid: 18924211
references.citation: Virology. 2004 Jul 1;324(2):297-310
references.pmid: 15207617
references.citation: Int J Pharm. 2000 Mar 20;197(1-2):221-31
references.pmid: 10704809
references.citation: Gene Ther. 2001 Apr;8(8):608-17
references.pmid: 11320407